O
THRD

OrbiMed’s Third Harmonic Bio THRD Stock Holding History

OrbiMed’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,779,071
Closed -$31.4M – 120
2025
Q2 		$31.4M Hold
5,779,071
– – 0.78% 32
2025
Q1 		$20.1M Hold
5,779,071
– – 0.48% 45
2024
Q4 		$59.5M Hold
5,779,071
– – 1.22% 27
2024
Q3 		$78.3M Hold
5,779,071
– – 1.42% 21
2024
Q2 		$75.1M Hold
5,779,071
– – 1.48% 18
2024
Q1 		$54.6M Hold
5,779,071
– – 1% 33
2023
Q4 		$63.4M Hold
5,779,071
– – 1.27% 29
2023
Q3 		$36.9M Hold
5,779,071
– – 0.78% 48
2023
Q2 		$27.8M Hold
5,779,071
– – 0.5% 60
2023
Q1 		$23.8M Hold
5,779,071
– – 0.47% 61
2022
Q4 		$24.9M Hold
5,779,071
– – 0.48% 60
2022
Q3 		$110M Buy
+5,779,071
New +$104M 2.04% 10

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $22.1B AUM 45.54% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

OrbiMed's THRD Position: Q3 2025 in Review

OrbiMed sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 5,779,071 shares — an estimated $31.4M sold.

OrbiMed first reported a position in THRD in Q3 2022 and held it in 12 quarters. The position peaked at $110M in Q3 2022. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • OrbiMed reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 5,779,071 Third Harmonic Bio shares in Q3 2025, an estimated $31.4M.
  • OrbiMed first reported a position in Third Harmonic Bio in Q3 2022 and held it in 12 quarters.
  • OrbiMed's Third Harmonic Bio position peaked at $110M in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.